Related Experiment Video

Updated: Jul 19, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Pneumothorax in cystic fibrosis: a retrospective case series

G M Hafen1, O C Ukoumunne, P J Robinson

  • 1Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Victoria, Australia. gaudenz.hafen@gmx.ch

Archives of Disease in Childhood
|October 24, 2006
PubMed

Insights

Pneumothorax, a complication in cystic fibrosis (CF), often leads to poor outcomes. This study reviews 11 CF patients with pneumothorax to understand their characteristics and treatment results.

Area of Science:

  • Pulmonary Medicine
  • Pediatric Respiratory Health
  • Cystic Fibrosis Research

Background:

  • Pneumothorax is a recognized complication in cystic fibrosis (CF) patients.
  • This condition is frequently linked to adverse clinical outcomes.

Purpose of the Study:

  • To describe the characteristics of CF patients who experienced pneumothorax.
  • To analyze sputum culture results, lung function, treatment, and outcomes in these patients.

Main Methods:

  • Retrospective review of medical records.
  • Analysis of data from 11 pediatric CF patients diagnosed with pneumothorax.
  • Data collected between 1990 and 2004 at a single tertiary pediatric hospital.

Main Results:

  • Detailed patient characteristics were documented.
  • Sputum culture findings, lung function parameters, and treatment interventions were recorded.
  • Patient outcomes following pneumothorax were assessed.

Conclusions:

  • Understanding pneumothorax in CF is crucial for improving patient management.
  • Further research may elucidate specific risk factors and optimal treatment strategies.
  • This case series provides insights into the clinical course of pneumothorax in pediatric CF.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome07:38

Design and Development of a Model to Study the Effect of Supplemental Oxygen on the Cystic Fibrosis Airway Microbiome

Published on: August 3, 2021

Related Concept Videos

Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Pneumothorax-I01:26

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax II: Pathophysiology01:08

Pneumothorax II: Pathophysiology

Pneumothorax means the presence of air in the pleural space — the thin potential gap between the visceral and parietal pleura. This condition disrupts the normal pressure balance that keeps the lungs inflated, leading to partial or complete collapse of the affected lung.Normal physiologyUnder normal conditions, the pleural space maintains a slightly negative intrapleural pressure, which keeps the lungs expanded against the chest wall. This negative pressure creates a delicate balance between...
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Atelectasis II: Pathophysiology01:10

Atelectasis II: Pathophysiology

Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...